From 2011 to 2018, an increase of 33% in overall sales (mg/PCU) of veterinary antimicrobial agents was noted in Poland.

The two most-sold classes were tetracyclines and penicillins. Sales of tetracyclines accounted for 36% of total sales in 2011, whereas in 2018, this figure was 28%. The corresponding figures for penicillins were 23% and 33%, indicating a shift in prescribing from tetracyclines to penicillins.
In 2015, the Ministry of Agriculture and Rural Development of the Republic of Poland developed a strategy to combat antimicrobial resistance. The implementation of the strategy involved five different parties covering different areas of responsibility, ranging from the prudent use of VMPs by veterinarians to conducting research on monitoring the rise of antimicrobial resistance.

To improve the system for collecting data on sales of veterinary medicines, the Ministry of Agriculture and Rural Development initiated work on amending corresponding regulations in order to specify the scope and process for gathering sales details. This resulted in increased quality of the data submitted from 2017.

Sales (mg/PCU) of 3rd- and 4th-generation cephalosporins increased slightly from 2011 to 2018. In 2011, this subclass accounted for 0.07% of total sales, while in 2018, this figure was 0.17%. In 2018, sales of 3rd- and 4th-generation cephalosporins VMPs were 0.28 mg/PCU, while aggregated sales for 25 countries in that year were 0.18 mg/PCU.

From 2011 to 2018, an increase was observed in sales (mg/PCU) of fluoroquinolones. In 2011, the proportion of total sales for fluoroquinolones was 5.7%, and in 2018, this figure was 6.5%. In 2018, sales of fluoroquinolones were 10.92 mg/PCU, while aggregated sales for 25 countries in that year were 2.42 mg/PCU.

Sales (mg/PCU) of other quinolones decreased between 2011 and 2018; in 2011, this subclass accounted for 0.06% of total sales, while in 2018, this figure was 0.01%. In 2018, sales of other quinolones were 0.01 mg/PCU, while aggregated sales for 25 countries in that year were 0.27 mg/PCU.

Sales (mg/PCU) of polymyxins increased by 80% from 2011 to 2018; in 2011, this class accounted for 3.3% of total sales; in 2018, this figure was 4.4%. In the same year, sales of polymyxins were 7.40 mg/PCU, while the aggregated sales for 25 countries in 2018 were 3.31 mg/PCU.